Immanuel Kim

Immanuel Kim is an associate in the Life Sciences group of the firm’s New York office. He represents both private and public life science clients in a broad range of transactions, including mergers and acquisitions, capital markets and venture financing deals. He also advises clients on corporate governance, Securities Exchange Act reporting requirements and other general corporate matters.

• Advised Graphite Bio, Inc. in its reverse merger with Lenz Therapeutics, Inc.
• Advised Magenta Therapeutics, Inc. in its reverse merger with Dianthus Therapeutics, Inc.
• Advised Societal CDMO, Inc. in its $35.6 million concurrent public offerings of common and preferred stock*
• Advised Renovacor, Inc. in its sale to Rocket Pharmaceuticals, Inc.*
• Advised Societal CDMO, Inc. in its $50 million acquisition of IRISYS, a San Diego-based CDMO*
• Advised Cognition Therapeutics, Inc. in its $45.2 million initial public offering*
• Advised Renovacor, Inc. in its merger with SPAC Chardan Healthcare Acquisitions 2 Corp. and concurrent private placement*

* Denotes experience prior to joining Goodwin

Immanuel serves as the Chair of Diversity, Equity, and Inclusion on the Recent Graduate Committee of the Fordham University School of Law and is a member of the Steering Committee of Jesus’ Witness Church.

Prior to joining Goodwin, Immanuel was an associate at other prominent law firms including Sidley Austin LLP and Troutman Pepper Hamilton Sanders LLP.

• Author, “A Voice for One, or a Voice for the People: Balancing Prosecutorial Speech Protections With Community Trust,” 86 Fordham L. Rev. 1331, 2017
• Author, “Another SAT Overhaul May Fail NYC Minority Students,” Fordham Urb. L.J.: City Square, 2016